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Comparison of symptomatic and
asymptomatic persons with Alzheimer
disease neuropathology
Advances in neuroimaging, biomarkers, and clinical
data have led to the hypothesis that the pathologic pro-
cess of Alzheimer dementia begins decades prior to
functional decline and diagnosis.1–3 High-profile clin-
ical trial results have shown that biomarker changes can
be made via pharmacologic intervention; however, the
timing of this intervention has likely been too late
to affect the cascade of neurodegenerative changes.4,5
In “Comparison of symptomatic and asymptomatic
persons with Alzheimer disease neuropathology” by
Monsell et al.,6 neuropathologic and clinical data were
used to determine the risk of developing clinically sig-
nificant cognitive impairment. This work represents a
significant contribution because it examines a large
cohort of autopsy data, which includes patients with
Alzheimer dementia neuropathology who were clini-
cally normal or diagnosed with mild cognitive impair-
ment and Alzheimer-type dementia. The authors report
a 3-fold increase in the risk of cognitive symptoms in
association with quantifiable increases in neurofibrillary
tangle pathology. In addition, several other factors,
including APOE gene status, history of depression,
and age, affected the clinical presentation. The ultimate
goal of this investigation and similar studies is to facil-
itate the early and accurate identification of those at risk
of developing Alzheimer dementia such that potentially
disease-modifying therapies may be considered.
HYPOTHESIS AND DESIGN The authors hypothe-
sized that there may be specific demographic, clinical,
or neuropathologic features that are associated with clin-
ical impairment consistent with a diagnosis of Alzheimer
dementia in a group of patients with known Alzheimer
dementia neuropathology at autopsy. The study design
is case-control with symptomatic dementia as the disease
state of interest.
METHODS The data used for this study were ex-
tracted from the National Alzheimer’s Coordinating
Center Uniform Data Set and Neuropathology Data
Set, which included 1,775 patients who underwent
autopsy from 2005 to 2012. Only patients who had a
clinical follow-up visit to one of the database centers
in the year prior to death were included. Other
inclusion criteria required the presence of both
diffuse plaques and neuritic plaques on pathologic
examination. This is important because it excluded
subjects with no Alzheimer dementia pathology and
also created a “control” group that was asymptomatic
clinically yet had neuropathologic changes consistent
with Alzheimer dementia. These parameters yielded
906 patients. This approach was derived from the
National Institute on Aging–Alzheimer’s Association
(NIA-AA) guidelines for the neuropathologic
assessment of Alzheimer dementia,7 which propose
the grading of Alzheimer dementia into 4 ranges
(not, low, intermediate, high) based on the “ABC”
score (A: Thal phase for Ab amyloid plaques; B:
Braak stage for neurofibrillary tangles; and C:
Consortium to Establish a Registry for Alzheimer’s
Disease neuritic plaque frequency). Notably, Thal
phase (the anatomical distribution of amyloid
plaques) was not available in the datasets used for
this study; however, the inclusion criteria were
designed to permit analysis of the largest number of
subjects with Alzheimer disease (AD) pathology, given
this limitation.
The determination of symptomatic disease was
based on the Clinical Dementia Rating scale
(CDR), a validated tool that evaluates 6 functional
domains and categorizes subjects’ dementia as none,
questionable/very mild, mild, moderate, or severe.8 In
this study, any classification greater than “none”
(CDR $ 0.5) was considered symptomatic. The
degree of pathologic changes and other clinical char-
acteristics were then evaluated using logistic regres-
sion models (first bivariate, then multivariate) to look
for associations with the clinical symptomatology.
The results of these analyses are the odds ratios
(ORs) of factors that lead to clinically symptomatic
dementia based on a cohort of patients with neuro-
pathologic changes consistent with Alzheimer
dementia.
RESULTS Demographic data reveal that the cohort
was 95% white, 45% female, 41% aged 80–89 years,
70% college-educated, and 49% had at least 1 APOE
e4 allele. The asymptomatic group included 82
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subjects, which represents only 9% of the total. The
authors point out that the asymptomatic population is
slightly older (mean 86.2 years vs 81.3). Also, 52.2%
of symptomatic patients had at least 1 APOE e4 allele,
compared to 16.2% of the asymptomatic group.
Neuropathologically, asymptomatic individuals were
more likely to have low B (neurofibrillary tangles) and
low C (neuritic plaques) scores (77%), and 50% of
the symptomatic group had both high B and high
C scores. In multivariate logistic regression, the
only factors that reached statistical significance in
asymptomatic subjects were older age, lower
Hachinski ischemic score, lack of APOE e4 allele,
and lower B score.
INTERPRETATION The authors sought to elucidate
risk factors that were associated with clinically sympto-
matic Alzheimer dementia in those with known Alz-
heimer dementia pathology. The design of this work
in the form of a case-control study is appropriate to
address the authors’ goals. Ideally the question that the
authors pose would be addressed by a prospective cohort
study, which follows patients from asymptomatic
enrollment until death; however, the logistics and
timing of such a study would likely be prohibitive at
present. One of the primary strengths of the study is the
number of patients with identified Alzheimer dementia
pathology via the current diagnostic gold standard,
postmortem neuropathologic examination. However,
the number of patients should be considered in the
context of an expected effect size for this study, which
was not reported. The weaknesses of the study lie mainly
in limitations of the available dataset. First, attempting to
apply the NIA-AA guidelines to the data is not perfect,
as a Thal phase for Ab plaques was not available.
According to the guidelines, the simplest way to
include all patients with Alzheimer dementia pathology
is to include all patients with at least Thal phase 1 (i.e.,
an ABC score of 1, X, X eliminates all “not” Alzheimer
dementia neuropathology). The C score of 1 or higher
used in this study (i.e., requiring the presence of neuritic
plaques) may have excluded some patients who would
have otherwise met criteria. Due to the limitations in the
assessment of diffuse plaques (and missing data in this
study), the scheme used by the authors likely led to the
most accurate classification possible. Amyloid imaging
techniques represent an emerging technology for
classifying patients with Alzheimer disease (AD)
pathology and may be useful for assigning Thal phase
in vivo in future prospective studies.
Another major limitation of the dataset is the
small “control” group, with only 9% of patients in
the asymptomatic group. One possible explanation
for this disparity in group sizes is a sampling bias in
which patients with clinical symptoms may be more
likely to consent to autopsy and to participate in AD
research. Based on current hypotheses of disease pro-
gression in Alzheimer dementia and accumulating
evidence of neuropathologic changes preceding symp-
tom onset, the predicted proportion of asymptomatic
subjects with Alzheimer dementia pathology would
be much higher than reported in this study. Another
challenge in interpreting these data is the oversimpli-
fied classification scheme of symptomatic vs asymp-
tomatic using the CDR. Categorization via the 5
stages of the CDR or use of the CDR sum of boxes
score, as opposed to a binary classification, may have
been a more clinically relevant assessment of degree of
impairment to correlate with risk factors.
The results of this study are presented as ORs,
which can be more difficult to interpret compared
to relative risk; however, ORs allow for easier adjust-
ment of potentially confounding covariates.9
Vascular pathology represents a known confound-
ing and contributing factor in the diagnosis of Alz-
heimer dementia. The investigators did attempt to
address this complex issue by pathologically identify-
ing the presence of large and small infarcts as well as
amyloid angiopathy. In addition, the Hachinski
ischemic score (HIS) was available for 79% of the
cohort. In multivariate analysis, only the HIS was cor-
related with symptomatic Alzheimer dementia, high-
lighting the relationship between Alzheimer dementia
and vascular pathology and the clinical significance of
attending to modifiable cerebrovascular risk factors in
attempts to maintain brain health.
A seemingly paradoxical observation was that
older age correlated with lower risk of symptomatic
disease. As the authors suggest, this finding may be
the result of a healthy survivor effect and a selection
bias of the control group, as persons with memory
concerns or a family history of Alzheimer dementia
are often compelled to enroll as normal control
subjects.
Overall, the authors were able to identify several
factors that were statistically significant in predicting
the presence of symptomatic disease. Of particular
interest, APOE e4 is strongly associated with symp-
tomatic disease even when adjustments have been
made for the underlying neuropathologic changes.
One could argue that based on the results of this
article, APOE e4 data and the Hachinski score are
relatively easily obtained and may aid in the predic-
tion of risk for developing symptomatic AD. Like-
wise, the importance of neurofibrillary tangles in
the development of symptomatic disease is empha-
sized in this neuropathologic study and consistent
with previous reports.10 Development of imaging
techniques specific to neurofibrillary tangles to com-
plement currently available amyloid imaging techni-
ques may also greatly improve the accuracy of
prediction of symptomatic AD.
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